Giovanni Caocci

Prof. Giovanni Caocci

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Artificial Intelligence in Medicine
Verified
Journal Article
Closed access
LORENZO PUTZULORENZO PUTZU
LORENZO PUTZU
GCGiovanni Caocci
Giovanni Caocci
Cecilia Di RubertoCecilia Di Ruberto
Cecilia Di Ruberto

12 July 2012 in Blood
Verified
Journal Article
Closed access
PDF file
MBMaria Ester Bernardo
Maria Ester Bernardo
EPEugenia Piras
Eugenia Piras
AVAdriana Vacca
Adriana Vacca
GGGiovanna Giorgiani
Giovanna Giorgiani
MZMarco Zecca
Marco Zecca
FLFranco Locatelli
Franco Locatelli
Sixty thalassemia patients (median age, 7 years; range, 1-37) underwent allogeneic hematopoietic stem cell transplantation (HSCT) after a preparation combining thiotepa, treosulfan, and fludarabine. Before HSCT, 27 children were assigned to risk class 1 of the Pesaro classification, 17 to class 2, and 4 to class 3; 12 patients were adults. Twenty patients were transplanted from an HLA-identical sibling and 40 from an unrelated donor. The cumulative incidence of graft failure and transplantation-related mortality was 9% and 7%, respectively. Eight patients experienced grade II-IV acute GVHD, the cumulative incidence being 14%. Among 56 patients at risk, 1 developed limited chronic GVHD. With a median follow-up of 36 months (range, 4-72), the 5-year probability of survival and thalassemia-free survival are 93% and 84%, respectively. Neither the class of risk nor the donor used influenced outcome. This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT.

1 November 2005 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GNGiorgio La Nasa
Giorgio La Nasa
FAFranca Argiolu
Franca Argiolu
CGClaudio Giardini
Claudio Giardini
Andrea PESSIONAndrea PESSION
Andrea PESSION
Franca FagioliFranca Fagioli
Franca Fagioli
FLFranco Locatelli
Franco Locatelli

1 September 2008 in Haematologica
Verified
Journal Article
Closed access
PDF file
ATA. A. Di Tucci
A. A. Di Tucci
GMG. Matta
G. Matta
SDS. Deplano
S. Deplano
AGA. Gabbas
A. Gabbas
CDC. Depau
C. Depau
EAEmanuele Angelucci
Emanuele Angelucci
Only limited data are available regarding myocardial iron overload in adult patients with transfusion dependent acquired anemias. To address this topic using MRI T2* we studied 27 consecutive chronic transfusion dependent patients with acquired anemias: (22 myelodysplastic syndrome, 5 primary myelofibrosis). Cardiac MRI T2* values obtained ranged from 5.6 to 58.7 (median value 39.8) milliseconds. Of the 24 analyzable patients, cardiac T2* correlated with transfusion burden ( p =0.0002). No patient who had received less than 290 mL/kg of packed red blood cells (101 units=20 grams of iron) had a pathological cardiac T2* value (< 20 ms). All patients who had received at least 24 PRBC units showed MRI T2* detectable hepatic iron (liver T2* value ≤6.3 ms). Only patients with severe hepatic iron overload (T2* <1.4 ms) showed cardiac T2* value indicative of dangerous myocardial iron deposition. Serum ferritin was not significantly correlated with cardiac T2* ( p =0.24). Gradient echo T2* magnetic resonance imaging provides a rapid and reproducible method for detecting myocardial iron overload which developed after a heavy transfusion burden equal to or greater than 290 mL/kg of packed red blood cell units.

9 August 2013 in Leukemia
Verified
Journal Article
Closed access
GCGiovanni Caocci
Giovanni Caocci
FMF Murgia
F Murgia
LPL Podda
L Podda
ASA Solinas
A Solinas
SAS Atzeni
S Atzeni
GNGiorgio La Nasa
Giorgio La Nasa

26 September 2013 in Blood
Verified
Journal Article
Closed access
GNGiorgio La Nasa
Giorgio La Nasa
GCGiovanni Caocci
Giovanni Caocci
FEFabio Efficace
Fabio Efficace
CDCarlo Dessì
Carlo Dessì
AVAdriana Vacca
Adriana Vacca
GLGuido Lucarelli
Guido Lucarelli
Key Points: HRQoL and lifestyles of patients transplanted more than 20 years ago for thalassemia are similar to those of the general population. Data on HRQoL in the long term provide both physicians and patients with a more complete picture of the advantages and potential risks of HSCT.